Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C

IMPORTANCE: Recent reports based on the US Food and Drug Administration’s voluntary Adverse Events Reporting System raised questions about the safety of direct-acting antivirals (DAAs) for treatment of the hepatitis C virus (HCV). OBJECTIVE: To assess the rates of adverse events in patients with HCV...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Netw Open
Main Authors: McGlynn, Elizabeth A., Adams, John L., Kramer, Jason, Sahota, Amandeep K., Silverberg, Michael J., Shenkman, Elizabeth, Nelson, David R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6563580/
https://ncbi.nlm.nih.gov/pubmed/31173117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.4765
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados